Skip to content

A prospective, double-blind, randomized controlled clinical study of Shenshuai II granule in delaying the progression of chronic glomerulonephritis (CKD3 stage)

A prospective, double-blind, randomized controlled clinical study of Shenshuai II granule in delaying the progression of chronic glomerulonephritis (CKD3 stage)

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003740
Enrollment
Unknown
Registered
2020-08-26
Start date
2020-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic glomerulonephritis (CKD3 stage)

Interventions

Sponsors

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. The patients who combined the diagnostic criteria of Western medicine for primary chronic glomerulonephritis (more than 50% of them had renal puncture case reports); 2. Patients aged 18-65 years old; 3. Patients with cgn-ckd3 (GFR 30-59ml/min) were diagnosed; 4. Patients with spleen kidney qi deficiency, dampness turbidity and blood stasis type were classified according to TCM syndrome differentiation; 5. Effective control of hypertension patients (blood pressure 130-90 / 80-60mmmhg), infection, water electrolyte and acid-base balance disorder; 6. Patients treated with ACEI / ARB for 2 weeks or without ACEI / ARB before enrollment; 7. Patients with 0.5g/24h <= 24h urinary protein <= 2.5g/24h; 8. Patients with informed consent. Those who meet the above criteria can be included in the observation cases, and those who are "no" in the above items can not be selected as selected cases.

Exclusion criteria

Exclusion criteria: 1. Patients with single kidney or with autosomal dominant polycystic kidney disease, acquired cyst and large renal space occupying disease. 2. Patients diagnosed with arrhythmia, acute renal failure or chronic renal failure with acute exacerbation. 3. Pregnant or preparing for pregnancy and lactation. 4. Those who are known to be allergic to such drugs, psychotic patients and patients who can not cooperate. 5. Patients who are participating in other drug clinical trials or have participated in other clinical trials within 3 months. 6. Patients who have used western medicine glucocorticoid, immunosuppressant and Tripterygium wilfordii preparation within three months. Those who are "yes" in any of the above items can not be included in the selected cases.

Design outcomes

Primary

MeasureTime frame
TCM syndrome integral;physical examination;Tongue image;Pulse condition;Adverse reactions / events;

Countries

China

Contacts

Public ContactChen Wang

Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine

chenwang42@163.com+86 13641836499

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026